Spots Global Cancer Trial Database for recurrent mantle cell lymphoma

Every month we try and update this database with for recurrent mantle cell lymphoma cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization
Modified Immune Cells (CD19/CD20 CAR-T Cells) in Treating Patients With Recurrent or Refractory B-Cell Lymphoma or Chronic Lymphocytic Leukemia	NCT04007029	CD19 Positive CD20 Positive Recurrent Chron... Recurrent Diffu... Recurrent Folli... Recurrent Mantl... Recurrent Prima... Recurrent Small... Refractory Chro... Refractory Diff... Refractory Foll... Refractory Mant... Refractory Prim... Refractory Smal...	Chimeric Antige... Cyclophosphamid... Fludarabine Pho... Tocilizumab	18 Years - 70 Years	Jonsson Comprehensive Cancer Center
Donor Umbilical Cord Blood Transplant in Treating Patients With Hematologic Cancer	NCT00723099	Acute Lymphobla... Acute Myeloid L... Aggressive Non-... Chronic Myeloge... Chronic Phase C... Indolent Non-Ho... Lymphoma Mixed Phenotype... Myelodysplastic... Myeloproliferat... Recurrent Chron... Recurrent Folli... Recurrent Lymph... Recurrent Mantl... Recurrent Margi... Recurrent Plasm... Recurrent Small... Recurrent T-Cel... Refractory Chro... Refractory Chro... Refractory Foll... Refractory Hodg... Refractory Lymp... Refractory Mant... Refractory Smal... T-Cell Non-Hodg...	Allogeneic Hema... Cyclophosphamid... Cyclosporine Fludarabine Pho... Laboratory Biom... Mycophenolate M... Total-Body Irra... Umbilical Cord ...	- 69 Years	Fred Hutchinson Cancer Center
Prevention of Graft-Versus-Host Disease in Patients With Advanced Leukemia or Lymphoma Who Are Eligible for Peripheral Stem Cell Transplantation	NCT00003056	Leukemia Lymphoma Graft Versus Ho...	cyclosporine cyclosporine an...	18 Years - 55 Years	Takeda
Pentostatin, Cyclophosphamide, Rituximab, and Mitoxantrone in Treating Patients With Chronic Lymphocytic Leukemia or Other Low-Grade B-Cell Cancer	NCT00546377	Leukemia Lymphoma	filgrastim pegfilgrastim rituximab sargramostim cyclophosphamid... mitoxantrone hy... pentostatin fluorescence in... gene rearrangem... polymerase chai... protein express... flow cytometry biopsy	18 Years - 120 Years	Memorial Sloan Kettering Cancer Center
Pevonedistat and Ibrutinib in Treating Participants With Relapsed or Refractory CLL or Non-Hodgkin Lymphoma	NCT03479268	B-Cell Prolymph... Recurrent Chron... Recurrent Diffu... Recurrent Folli... Recurrent Lymph... Recurrent Mantl... Recurrent Margi... Recurrent Non-H... Recurrent Small... Refractory Chro... Refractory Diff... Refractory Foll... Refractory Lymp... Refractory Mant... Refractory Marg... Refractory Non-... Refractory Smal... Richter Syndrom...	Ibrutinib Laboratory Biom... Pevonedistat Pharmacokinetic... Pharmacological...	18 Years -	City of Hope Medical Center
Irradiated Donor Lymphocytes and Rituximab in Treating Patients With Relapsed or Refractory Lymphoproliferative Disease	NCT00176475	Leukemia Lymphoma Multiple Myelom...	rituximab therapeutic all...	18 Years -	Rutgers, The State University of New Jersey
Combination Chemotherapy With or Without Amifostine in Treating Patients With Recurrent or Refractory Non-Hodgkin's Lymphoma or Hodgkin's Disease Undergoing Stem Cell Transplantation	NCT00003143	Lymphoma	Amifostine DHAP	18 Years -	Jonsson Comprehensive Cancer Center
Combination Chemotherapy Followed By Autologous Stem Cell Transplant, and White Blood Cell Infusions in Treating Patients With Non-Hodgkin's Lymphoma	NCT00244946	Lymphoma	therapeutic aut... carmustine cytarabine etoposide melphalan peripheral bloo...	15 Years - 70 Years	Barbara Ann Karmanos Cancer Institute
Memory-enriched CAR-T Cells Immunotherapy for B Cell Lymphoma	NCT02652910	Recurrent Adult... Recurrent Folli... Recurrent Mantl... Stage III Adult... Stage III Folli... Stage III Mantl... Stage IV Adult ... Stage IV Follic... Stage IV Mantle...	CD19.CAR-T cell...	18 Years - 70 Years	Xinqiao Hospital of Chongqing
Obatoclax and Bortezomib in Treating Patients With Aggressive Relapsed or Recurrent Non-Hodgkin Lymphoma	NCT00538187	Adult Non-Hodgk... Recurrent Adult... Recurrent Grade... Recurrent Grade... Recurrent Grade... Recurrent Mantl... Recurrent Margi... Recurrent Small...	obatoclax mesyl... bortezomib laboratory biom... pharmacological...	18 Years -	National Cancer Institute (NCI)
Ixazomib and Rituximab in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma	NCT04047797	Recurrent Mantl... Refractory Mant...	Ixazomib Ixazomib Citrat... Rituximab	18 Years -	M.D. Anderson Cancer Center
Monoclonal Antibody Therapy in Treating Patients With Follicular or Mantle Cell Lymphoma	NCT00003280	Lymphoma	rituximab	18 Years - 120 Years	Swiss Group for Clinical Cancer Research
Yttrium Y 90 Ibritumomab Tiuxetan, Fludarabine, Radiation Therapy, and Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma	NCT00119392	B-cell Chronic ... Nodal Marginal ... Recurrent Adult... Recurrent Adult... Recurrent Adult... Recurrent Adult... Recurrent Adult... Recurrent Adult... Recurrent Adult... Recurrent Grade... Recurrent Grade... Recurrent Grade... Recurrent Mantl... Recurrent Margi... Recurrent Small... Splenic Margina... Waldenström Mac...	rituximab cyclosporine fludarabine pho... mycophenolate m... yttrium Y 90 ib... peripheral bloo... allogeneic hema... total-body irra...	18 Years -	Fred Hutchinson Cancer Center
Patient-Derived Xenografts in Personalizing Treatment for Patients With Relapsed/Refractory Mantle Cell Lymphoma	NCT03219047	Recurrent Mantl... Refractory Mant...	Best Practice Ibrutinib Patient Derived... Personalized Me...	18 Years -	M.D. Anderson Cancer Center
Bortezomib and Gemcitabine in Treating Patients With Relapsed B-Cell Non-Hodgkin Lymphoma	NCT00863369	Lymphoma	rituximab bortezomib gemcitabine hyd... questionnaire a...	18 Years -	City of Hope Medical Center
Monoclonal Antibody Therapy and Peripheral Stem Cell Transplant in Treating Patients With Non-Hodgkin's Lymphoma	NCT00017381	Contiguous Stag... Contiguous Stag... Contiguous Stag... Contiguous Stag... Contiguous Stag... Contiguous Stag... Contiguous Stag... Contiguous Stag... Extranodal Marg... Noncontiguous S... Noncontiguous S... Noncontiguous S... Noncontiguous S... Noncontiguous S... Noncontiguous S... Noncontiguous S... Noncontiguous S... Recurrent Adult... Recurrent Adult... Recurrent Grade... Recurrent Grade... Recurrent Grade... Recurrent Mantl... Recurrent Margi... Recurrent Small... Stage I Adult D... Stage I Adult D... Stage I Grade 1... Stage I Grade 2... Stage I Grade 3... Stage I Mantle ... Stage I Margina... Stage I Small L... Stage III Adult... Stage III Adult... Stage III Grade... Stage III Grade... Stage III Grade... Stage III Mantl... Stage III Margi... Stage III Small... Stage IV Adult ... Stage IV Adult ... Stage IV Grade ... Stage IV Grade ... Stage IV Grade ... Stage IV Mantle... Stage IV Margin... Stage IV Small ... Waldenström Mac...	rituximab cyclophosphamid... filgrastim yttrium Y 90 ib... peripheral bloo...	18 Years - 70 Years	National Cancer Institute (NCI)
Bortezomib and Lenalidomide in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma	NCT00553644	Recurrent Mantl...	Bortezomib Laboratory Biom... Lenalidomide	18 Years -	National Cancer Institute (NCI)
Flavopiridol in Treating Patients With Recurrent Intermediate-Grade or High-Grade Non-Hodgkin's Lymphoma or Mantle Cell Lymphoma	NCT00003039	Lymphoma	alvocidib	18 Years -	National Cancer Institute (NCI)
Bortezomib, Rituximab, and Dexamethasone With or Without Temsirolimus in Treating Patients With Untreated or Relapsed Waldenstrom Macroglobulinemia or Relapsed or Refractory Mantle Cell or Follicular Lymphoma	NCT01381692	Recurrent Folli... Recurrent Mantl... Recurrent Margi... Recurrent Non-H... Recurrent Small... Recurrent Walde... Refractory Foll... Refractory Mant... Refractory Marg... Refractory Non-... Refractory Smal...	Bortezomib Dexamethasone Laboratory Biom... Quality-of-Life... Rituximab Temsirolimus	18 Years -	National Cancer Institute (NCI)
10-Propargyl-10-Deazaaminopterin in Treating Patients With Recurrent or Refractory Non-Hodgkin's Lymphoma or Hodgkin's Lymphoma	NCT00052442	Lymphoma	pralatrexate	18 Years -	Spectrum Pharmaceuticals, Inc
Bortezomib, Cladribine, and Rituximab in Treating Patients With Advanced Mantle Cell Lymphoma or Indolent Lymphoma	NCT00980395	Lymphoma Mantle Cell Lym... Indolent Lympho... SLL	rituximab bortezomib cladribine	18 Years -	University of Arizona
Bortezomib and Rituximab in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma	NCT00265928	Lymphoma	bortezomib rituximab antibody therap... biological ther... enzyme inhibito... monoclonal anti...	18 Years -	National Cancer Institute (NCI)
SB-715992 in Treating Patients With Metastatic or Unresectable Solid Tumors or Hodgkin's or Non-Hodgkin's Lymphoma	NCT00101244	Adult Grade III... Extranodal Marg... Nodal Marginal ... Recurrent Adult... Recurrent Adult... Recurrent Adult... Recurrent Adult... Recurrent Adult... Recurrent Adult... Recurrent Adult... Recurrent Adult... Recurrent Grade... Recurrent Grade... Recurrent Grade... Recurrent Mantl... Recurrent Margi... Recurrent Small... Splenic Margina... Stage IV Adult ... Stage IV Adult ... Stage IV Adult ... Stage IV Adult ... Stage IV Adult ... Stage IV Adult ... Stage IV Adult ... Stage IV Grade ... Stage IV Grade ... Stage IV Grade ... Stage IV Mantle... Stage IV Margin... Stage IV Small ... Unspecified Adu... Waldenström Mac...	ispinesib laboratory biom... pharmacological...	18 Years -	National Cancer Institute (NCI)
Bortezomib, Rituximab, and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Relapsed or Refractory Low-Grade, Follicular, or Mantle Cell Non-Hodgkin's Lymphoma	NCT00334438	Lymphoma	rituximab bortezomib yttrium Y 90 ib... Indium 111 ibri...	18 Years - 120 Years	UNC Lineberger Comprehensive Cancer Center
Analysis of Dendritic Phenotype and Function of Patients Receiving VEGF-Trap on VGFT-ST-0202	NCT00896662	Lymphoma Solid Tumor	immunologic tec... laboratory biom... pharmacological...	18 Years -	Vanderbilt-Ingram Cancer Center
Rituximab, Fludarabine, Cyclophosphamide, and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Relapsed B-Cell Non-Hodgkin's Lymphoma	NCT00397800	Lymphoma	rituximab cyclophosphamid... fludarabine pho... yttrium Y 90 ib...	50 Years - 75 Years	Technical University of Munich
Combination Chemotherapy Plus Rituximab in Treating Patients With Relapsed Non-Hodgkin's Lymphoma	NCT00005601	Lymphoma	rituximab cisplatin cytarabine dexamethasone sargramostim	18 Years -	Alliance for Clinical Trials in Oncology
Rituximab & Combination Chemotherapy Followed by Transplantation in Relapsed or Refractory Non-Hodgkin's Lymphoma	NCT00007852	Lymphoma	rituximab carmustine cytarabine etoposide melphalan autologous hema...	19 Years -	University of Nebraska
Alisertib, Bortezomib, and Rituximab in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma or B-cell Low Grade Non-Hodgkin Lymphoma	NCT01695941	Recurrent B-Cel... Recurrent Mantl... Refractory B-Ce... Refractory Mant...	Alisertib Bortezomib Laboratory Biom... Rituximab	18 Years -	National Cancer Institute (NCI)
Everolimus in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma	NCT00516412	Lymphoma	everolimus molecular respo...	18 Years -	Swiss Group for Clinical Cancer Research
Everolimus in Treating Older Patients With Mantle Cell Lymphoma Previously Treated With First-Line or Second-Line Chemotherapy	NCT00727207	Lymphoma	everolimus	40 Years -	Technical University of Munich
Polatuzumab Vedotin, Venetoclax, and Rituximab and Hyaluronidase Human for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma	NCT04659044	Recurrent B-Cel... Recurrent Grade... Recurrent Grade... Recurrent Grade... Recurrent Mantl... Recurrent Margi... Recurrent Small... Refractory B-Ce... Refractory Grad... Refractory Grad... Refractory Grad... Refractory Mant... Refractory Marg... Refractory Smal...	Polatuzumab Ved... Rituximab Rituximab and H... Venetoclax	18 Years -	Academic and Community Cancer Research United
Rituximab, Cyclophosphamide, and Pegfilgrastim in Treating Patients With Leukemia or Non-Hodgkin's Lymphoma	NCT00278161	Leukemia Lymphoma	Pegfilgrastim Rituximab Cyclophosphamid...	18 Years - 70 Years	Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Colony-Stimulating Factors to Relieve Neutropenia in Patients With Recurrent Non-Hodgkin's Lymphoma	NCT00004192	Lymphoma Neutropenia	filgrastim pegfilgrastim cisplatin cytarabine etoposide methylprednisol...	18 Years - 120 Years	University of Nebraska
Peripheral Stem Cell Transplantation in Treating Patients With Multiple Myeloma or Other B-cell Cancers	NCT00003163	Lymphoma Multiple Myelom...	filgrastim sargramostim cyclophosphamid... melphalan autologous bone... peripheral bloo... radiation thera...	18 Years -	National Cancer Institute (NCI)
CCI-779 and Rituximab in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma	NCT00109967	Recurrent Mantl...	rituximab temsirolimus	18 Years -	National Cancer Institute (NCI)
Sorafenib in Treating Patients With Metastatic or Unresectable Solid Tumors, Multiple Myeloma, or Non-Hodgkin's Lymphoma With or Without Impaired Liver or Kidney Function	NCT00118170	Extranodal Marg... Nodal Marginal ... Recurrent Adult... Recurrent Adult... Recurrent Adult... Recurrent Adult... Recurrent Adult... Recurrent Adult... Recurrent Adult... Recurrent Grade... Recurrent Grade... Recurrent Grade... Recurrent Mantl... Recurrent Margi... Recurrent Small... Refractory Mult... Splenic Margina... Stage II Multip... Stage III Adult... Stage III Adult... Stage III Adult... Stage III Adult... Stage III Adult... Stage III Adult... Stage III Grade... Stage III Grade... Stage III Grade... Stage III Mantl... Stage III Margi... Stage III Multi... Stage III Small... Stage IV Adult ... Stage IV Adult ... Stage IV Adult ... Stage IV Adult ... Stage IV Adult ... Stage IV Adult ... Stage IV Grade ... Stage IV Grade ... Stage IV Grade ... Stage IV Mantle... Stage IV Margin... Stage IV Small ... Unspecified Adu... Waldenström Mac...	sorafenib tosyl... pharmacological...	18 Years -	National Cancer Institute (NCI)
Combination Chemotherapy Plus Rituximab in Treating Patients With Recurrent or Refractory Non-Hodgkin's Lymphoma	NCT00007865	Lymphoma	rituximab carboplatin etoposide ifosfamide	19 Years - 120 Years	University of Nebraska
Flavopiridol in Treating Patients With Recurrent Intermediate-Grade or High-Grade Non-Hodgkin's Lymphoma or Mantle Cell Lymphoma	NCT00003039	Lymphoma	alvocidib	18 Years -	National Cancer Institute (NCI)
Rituximab and Liposomal Doxorubicin in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma	NCT00244985	Lymphoma	rituximab pegylated lipos...	18 Years - 120 Years	Roswell Park Cancer Institute
Bortezomib, Rituximab, and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Relapsed or Refractory Low-Grade, Follicular, or Mantle Cell Non-Hodgkin's Lymphoma	NCT00334438	Lymphoma	rituximab bortezomib yttrium Y 90 ib... Indium 111 ibri...	18 Years - 120 Years	UNC Lineberger Comprehensive Cancer Center
Chemotherapy, Radiation Therapy, and Umbilical Cord Blood Transplantation in Treating Patients With Hematologic Cancer	NCT00003661	Graft Versus Ho... Leukemia Lymphoma Myelodysplastic... Neuroblastoma	anti-thymocyte ... busulfan cyclosporine melphalan methylprednisol... umbilical cord ... radiation thera...	- 54 Years	Roswell Park Cancer Institute
Denileukin Diftitox in Treating Patients With Non-Hodgkin's Lymphoma	NCT00026429	Leukemia Lymphoma	denileukin dift...	18 Years -	National Cancer Institute (NCI)
Alisertib With and Without Rituximab in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma	NCT01812005	Extranodal Marg... Nodal Marginal ... Recurrent Adult... Recurrent Adult... Recurrent Grade... Recurrent Grade... Recurrent Grade... Recurrent Mantl... Recurrent Margi... Splenic Margina... Waldenström Mac...	alisertib rituximab laboratory biom...	18 Years -	Ohio State University Comprehensive Cancer Center
Combination Chemotherapy With or Without Amifostine in Treating Patients With Recurrent or Refractory Non-Hodgkin's Lymphoma or Hodgkin's Disease Undergoing Stem Cell Transplantation	NCT00003143	Lymphoma	Amifostine DHAP	18 Years -	Jonsson Comprehensive Cancer Center
Intravenous VEGF Trap in Treating Patients With Relapsed or Refractory Advanced Solid Tumors or Non-Hodgkin's Lymphoma	NCT00082823	Cancer	ziv-aflibercept	18 Years - 120 Years	Regeneron Pharmaceuticals
Genetically Modified T-Cell Therapy in Treating Patients With Advanced ROR1+ Malignancies	NCT02706392	Hematopoietic a... Malignant Solid... Metastatic Lung... Metastatic Trip... Recurrent Acute... Recurrent Mantl... Refractory Chro... Stage III Lung ... Stage IIIA Lung... Stage IIIB Lung... Stage IV Breast... Stage IV Lung N... Unresectable Lu...	Laboratory Biom... ROR1 CAR-specif...	18 Years -	Fred Hutchinson Cancer Center
Nivolumab for Relapsed, Refractory, or Detectable Disease Post Chimeric Antigen Receptor T-cell Treatment in Patients With Hematologic Malignancies	NCT04205409	Recurrent Chron... Recurrent Diffu... Recurrent Folli... Recurrent Grade... Recurrent Grade... Recurrent Grade... Recurrent Grade... Recurrent Margi... Recurrent Non-H... Recurrent Plasm... Refractory Chro... Refractory Diff... Refractory Foll... Refractory Marg... Refractory Non-... Refractory Plas... Recurrent Mantl... Refractory Mant...	Nivolumab	18 Years -	University of Washington
Bryostatin 1 in Treating Patients With Relapsed Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia	NCT00002908	Leukemia Lymphoma	bryostatin 1 vincristine sul...	18 Years -	Barbara Ann Karmanos Cancer Institute
FR901228 in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma	NCT00383565	Recurrent Adult... Recurrent Mantl...	romidepsin	18 Years -	National Cancer Institute (NCI)
Rituximab Plus Interleukin-2 in Treating Patients With Lymphoma	NCT00003356	Lymphoma	aldesleukin rituximab	18 Years - 75 Years	University of Rochester
Interferon-Beta-1a (FP-1201) to Prevent Toxicities After CD19-Directed CAR T-Cell Therapy	NCT05936229	Recurrent B Acu... Recurrent B-Cel... Refractory B Ac... Refractory B-Ce... Recurrent Mantl... Refractory Mant...	Interferon Beta... X-Ray Imaging Echocardiograph... Multigated Acqu... Computed Tomogr... Positron Emissi... Lumbar Puncture Bone Marrow Asp... Bone Marrow Bio... Biospecimen Col... Biopsy	18 Years -	Fred Hutchinson Cancer Center
Phase II Trial With Correlative Laboratory Studies of Single Agent Irinotecan (Camptosar CPT-11)	NCT00005626	Leukemia Lymphoma	Irinotecan	18 Years -	H. Lee Moffitt Cancer Center and Research Institute
Peripheral Stem Cell Transplantation Plus Combination Chemotherapy and Monoclonal Antibody Therapy in Treating Patients With Non-Hodgkin's Lymphoma	NCT00003397	Lymphoma	filgrastim rituximab sargramostim carmustine cisplatin cyclophosphamid... dexamethasone etoposide gemcitabine hyd... melphalan paclitaxel bone marrow abl... peripheral bloo...	18 Years - 75 Years	University of Maryland, Baltimore
Pevonedistat and Ibrutinib in Treating Participants With Relapsed or Refractory CLL or Non-Hodgkin Lymphoma	NCT03479268	B-Cell Prolymph... Recurrent Chron... Recurrent Diffu... Recurrent Folli... Recurrent Lymph... Recurrent Mantl... Recurrent Margi... Recurrent Non-H... Recurrent Small... Refractory Chro... Refractory Diff... Refractory Foll... Refractory Lymp... Refractory Mant... Refractory Marg... Refractory Non-... Refractory Smal... Richter Syndrom...	Ibrutinib Laboratory Biom... Pevonedistat Pharmacokinetic... Pharmacological...	18 Years -	City of Hope Medical Center
Donor White Blood Cell Infusions and Interleukin-2 in Treating Patients Who Are Undergoing an Autologous Stem Cell Transplant for Relapsed Advanced Lymphoid Cancer	NCT00248430	Graft Versus Ho... Leukemia Lymphoma Multiple Myelom...	aldesleukin therapeutic all... melphalan bone marrow abl... peripheral bloo...	18 Years - 69 Years	Fred Hutchinson Cancer Center
Sorafenib in Treating Patients With Metastatic or Unresectable Solid Tumors, Multiple Myeloma, or Non-Hodgkin's Lymphoma With or Without Impaired Liver or Kidney Function	NCT00118170	Extranodal Marg... Nodal Marginal ... Recurrent Adult... Recurrent Adult... Recurrent Adult... Recurrent Adult... Recurrent Adult... Recurrent Adult... Recurrent Adult... Recurrent Grade... Recurrent Grade... Recurrent Grade... Recurrent Mantl... Recurrent Margi... Recurrent Small... Refractory Mult... Splenic Margina... Stage II Multip... Stage III Adult... Stage III Adult... Stage III Adult... Stage III Adult... Stage III Adult... Stage III Adult... Stage III Grade... Stage III Grade... Stage III Grade... Stage III Mantl... Stage III Margi... Stage III Multi... Stage III Small... Stage IV Adult ... Stage IV Adult ... Stage IV Adult ... Stage IV Adult ... Stage IV Adult ... Stage IV Adult ... Stage IV Grade ... Stage IV Grade ... Stage IV Grade ... Stage IV Mantle... Stage IV Margin... Stage IV Small ... Unspecified Adu... Waldenström Mac...	sorafenib tosyl... pharmacological...	18 Years -	National Cancer Institute (NCI)
Tafasitamab, Lenalidomide and Venetoclax for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma	NCT05910801	Recurrent Mantl... Refractory Mant...	Biopsy Biospecimen Col... Bone Marrow Asp... Bone Marrow Bio... Computed Tomogr... Lenalidomide Lumbar Puncture Magnetic Resona... Positron Emissi... Tafasitamab Venetoclax	18 Years -	Academic and Community Cancer Research United
Combination Chemotherapy With or Without Idarubicin and Peripheral Stem Cell Transplantation in Treating Patients With Leukemia or Myelodysplastic Syndrome	NCT00002989	Leukemia Lymphoma Multiple Myelom... Myelodysplastic...	busulfan cyclophosphamid... idarubicin melphalan radiation thera...	16 Years - 60 Years	National Cancer Institute (NCI)
Biological Therapy Plus Monoclonal Antibody Therapy in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma	NCT00040950	Lymphoma	rituximab agatolimod sodi...	18 Years -	National Cancer Institute (NCI)
Epirubicin and Rituximab in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia	NCT00062296	Leukemia Lymphoma	rituximab epirubicin hydr...	18 Years -	Fox Chase Cancer Center
Ibrutinib in Treating Patients With Refractory or Relapsed Lymphoma After Donor Stem Cell Transplant	NCT02869633	Blastoid Varian... Recurrent Chron... Recurrent Folli... Recurrent Hodgk... Recurrent Mantl... Refractory Chro... Refractory Foll... Refractory Hodg... Refractory Mant...	Ibrutinib Laboratory Biom...	18 Years -	Vanderbilt-Ingram Cancer Center
Clofarabine and Rituximab in Treating Patients With Relapsed Non-Hodgkin Lymphoma	NCT00691652	Lymphoma	rituximab clofarabine DNA methylation... gene expression... microarray anal... polymerase chai... high performanc... laboratory biom...	18 Years - 89 Years	OHSU Knight Cancer Institute
Lenalidomide And Rituximab as Maintenance Therapy in Treating Patients With B-Cell Non-Hodgkin Lymphoma	NCT01045928	Adult Non-Hodgk... Adult Grade III... Contiguous Stag... Contiguous Stag... Contiguous Stag... Contiguous Stag... Contiguous Stag... Contiguous Stag... Contiguous Stag... Contiguous Stag... Contiguous Stag... Contiguous Stag... Contiguous Stag... Contiguous Stag... Cutaneous B-cel... Extranodal Marg... Nodal Marginal ... Noncontiguous S... Noncontiguous S... Noncontiguous S... Noncontiguous S... Noncontiguous S... Noncontiguous S... Noncontiguous S... Noncontiguous S... Noncontiguous S... Noncontiguous S... Noncontiguous S... Noncontiguous S... Recurrent Adult... Recurrent Adult... Recurrent Adult... Recurrent Adult... Recurrent Adult... Recurrent Adult... Recurrent Adult... Recurrent Grade... Recurrent Grade... Recurrent Grade... Recurrent Mantl... Recurrent Margi... Recurrent Small... Splenic Margina... Stage I Adult B... Stage I Adult D... Stage I Adult D... Stage I Adult D... Stage I Adult I... Stage I Adult L... Stage I Grade 1... Stage I Grade 2... Stage I Grade 3... Stage I Mantle ... Stage I Margina... Stage I Small L... Stage III Adult... Stage III Adult... Stage III Adult... Stage III Adult... Stage III Adult... Stage III Adult... Stage III Grade... Stage III Grade... Stage III Grade... Stage III Mantl... Stage III Margi... Stage III Small... Stage IV Adult ... Stage IV Adult ... Stage IV Adult ... Stage IV Adult ... Stage IV Adult ... Stage IV Adult ... Stage IV Grade ... Stage IV Grade ... Stage IV Grade ... Stage IV Mantle... Stage IV Margin... Stage IV Small ... Waldenstrom Mac...	lenalidomide rituximab polymerase chai... nucleic acid se... polymorphism an... flow cytometry laboratory biom...	18 Years -	Case Comprehensive Cancer Center
17-AAG in Treating Patients With Relapsed or Refractory Anaplastic Large Cell Lymphoma, Mantle Cell Lymphoma, or Hodgkin's Lymphoma	NCT00117988	Anaplastic Larg... Recurrent Adult... Recurrent Mantl...	tanespimycin	16 Years -	National Cancer Institute (NCI)
Venetoclax and Acalabrutinib in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma	NCT03946878	Blastoid Varian... CCND1 Protein O... CD20 Positive CD5 Positive FCER2 Negative Pleomorphic Var... Recurrent Mantl... Refractory Mant... t(11;14)(q13;q3...	Acalabrutinib Venetoclax	18 Years -	M.D. Anderson Cancer Center
Everolimus and Bendamustine Hydrochloride in Treating Patients With Relapsed or Refractory Hematologic Cancer	NCT02240719	Recurrent Adult... Recurrent Adult... Recurrent Grade... Recurrent Grade... Recurrent Grade... Recurrent Mantl... Refractory Chro... Multiple Myelom...	everolimus bendamustine hy...	18 Years -	University of California, Davis
T-Regulatory Cell Infusion Post Umbilical Cord Blood Transplant in Patients With Advanced Hematologic Cancer	NCT00602693	Leukemia Lymphoma Multiple Myelom... Plasma Cell Neo... Myelodysplastic...	umbilical cord ... Allopurinol fludarabine pho... Cyclophosphamid... Total body irra... Treg infusion Sirolimus	18 Years - 75 Years	Masonic Cancer Center, University of Minnesota
Ibrutinib and Rituximab in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma or Older Patients With Newly Diagnosed Mantle Cell Lymphoma	NCT01880567	CCND1 Positive CCND2 Positive CCND3 Positive CD20 Positive Mantle Cell Lym... Recurrent Mantl... Refractory Mant...	Ibrutinib Laboratory Biom... Rituximab	18 Years -	M.D. Anderson Cancer Center
UCN-01 in Treating Patients With Advanced Cancer	NCT00003289	Leukemia Lymphoma Unspecified Adu...	7-hydroxystauro...	18 Years -	Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Iodine I 131 Tositumomab and Fludarabine Phosphate in Treating Older Patients Who Are Undergoing an Autologous or Syngeneic Stem Cell Transplant for Relapsed or Refractory Non-Hodgkin's Lymphoma	NCT00110071	Extranodal Marg... Nodal Marginal ... Recurrent Adult... Recurrent Adult... Recurrent Adult... Recurrent Adult... Recurrent Adult... Recurrent Adult... Recurrent Grade... Recurrent Grade... Recurrent Grade... Recurrent Mantl... Recurrent Margi... Splenic Margina... Waldenström Mac...	fludarabine pho... peripheral bloo... iodine I 131 to... laboratory biom... flow cytometry polymerase chai...	60 Years -	Fred Hutchinson Cancer Center
Rituximab Plus Interleukin-2 in Treating Patients With Hematologic Cancer	NCT00010192	B-cell Adult Ac... Extranodal Marg... Nodal Marginal ... Noncontiguous S... Noncontiguous S... Noncontiguous S... Noncontiguous S... Noncontiguous S... Noncontiguous S... Noncontiguous S... Noncontiguous S... Noncontiguous S... Noncontiguous S... Noncontiguous S... Noncontiguous S... Recurrent Adult... Recurrent Adult... Recurrent Adult... Recurrent Adult... Recurrent Adult... Recurrent Adult... Recurrent Adult... Recurrent Grade... Recurrent Grade... Recurrent Grade... Recurrent Mantl... Recurrent Margi... Recurrent Small... Splenic Margina... Stage III Adult... Stage III Adult... Stage III Adult... Stage III Adult... Stage III Adult... Stage III Adult... Stage III Grade... Stage III Grade... Stage III Grade... Stage III Mantl... Stage III Margi... Stage III Small... Stage IV Adult ... Stage IV Adult ... Stage IV Adult ... Stage IV Adult ... Stage IV Adult ... Stage IV Adult ... Stage IV Grade ... Stage IV Grade ... Stage IV Grade ... Stage IV Mantle... Stage IV Margin... Stage IV Small ...	rituximab aldesleukin laboratory biom... pharmacological...	18 Years -	National Cancer Institute (NCI)
Fludarabine Plus Octreotide in Treating Patients With Relapsed Low-Grade Non-Hodgkin's Lymphoma	NCT00002779	Lymphoma	fludarabine pho... octreotide acet...	18 Years -	Alliance for Clinical Trials in Oncology
Rituximab, Romidepsin, and Lenalidomide in Treating Patients With Recurrent or Refractory B-cell Non-Hodgkin Lymphoma	NCT02281279	B-cell Adult Ac... Extranodal Marg... Intraocular Lym... Nodal Marginal ... Recurrent Adult... Recurrent Adult... Recurrent Adult... Recurrent Adult... Recurrent Adult... Recurrent Adult... Recurrent Adult... Recurrent Adult... Recurrent Grade... Recurrent Grade... Recurrent Grade... Recurrent Mantl... Recurrent Margi... Recurrent Small... Refractory Hair... Small Intestine... Splenic Margina... Testicular Lymp... Waldenström Mac...	rituximab lenalidomide romidepsin laboratory biom...	18 Years -	Mayo Clinic
Lenalidomide, Umbralisib, and Ublituximab for the Treatment of Relapsed or Refractory Indolent Non-Hodgkin Lymphoma or Mantle Cell Lymphoma	NCT04635683	Recurrent B-Cel... Recurrent Extra... Recurrent Folli... Recurrent Grade... Recurrent Grade... Recurrent Grade... Recurrent Lymph... Recurrent Mantl... Recurrent Margi... Recurrent Nodal... Recurrent Splen... Recurrent Walde... Refractory B-Ce... Refractory Extr... Refractory Foll... Refractory Grad... Refractory Grad... Refractory Grad... Refractory Lymp... Refractory Mant... Refractory Marg... Refractory Noda... Refractory Sple... Refractory Wald...	Lenalidomide Ublituximab Umbralisib	18 Years -	Ohio State University Comprehensive Cancer Center
PS-341 in Treating Patients With Advanced Cancer	NCT00006362	Leukemia Lymphoma Multiple Myelom... Precancerous Co... Unspecified Adu...	bortezomib	18 Years -	Mayo Clinic
Epoetin Alfa in Treating Anemia in Patients With Lymphoma, Chronic Lymphocytic Leukemia, or Multiple Myeloma and Anemia Caused By Chemotherapy	NCT00003341	Anemia Leukemia Lymphoma Multiple Myelom...	epoetin alfa quality-of-life...	18 Years -	Memorial Sloan Kettering Cancer Center
Chemotherapy and Total-Body Irradiation Followed by Donor Umbilical Cord Blood Transplant, Cyclosporine, and Mycophenolate Mofetil in Treating Patients With Hematologic Cancer	NCT00290641	Chronic Myelopr... Leukemia Lymphoma Myelodysplastic...	filgrastim graft-versus-tu... cyclophosphamid... cyclosporine fludarabine pho... mycophenolate m... umbilical cord ... radiation thera...	- 45 Years	Masonic Cancer Center, University of Minnesota
Fludarabine and Cyclophosphamide Followed by Peripheral Stem Cell Transplant in Treating Patients With Leukemia or Lymphoma	NCT00006252	Leukemia Lymphoma	fludarabine pho... Cyclophosphamid... PBSC G-CSF Donor lymphocyt...	- 69 Years	Alliance for Clinical Trials in Oncology
Interrogating Biological Signaling Pathway Dysregulations and In Vitro Screening With Personalized Therapies in Relapsed or Refractory Mantle Cell Lymphoma, MCL MATCH Trial	NCT04872413	Recurrent Mantl... Refractory Mant...	Biospecimen Col... Follow-Up	18 Years -	M.D. Anderson Cancer Center

Take Control of Your Skin and Body Changes Today.

Try out Spots for free, set up only takes 2 mins.

Join others from around the world: